NSHO-101: Dose form - tablet Route of administration - oral Regimen / Treatment period - QD for 14 days
Study summary
The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of NSHO-101 in Healthy Participants.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* Participants (males and females) at least 18 years of age
* Ability to provide written informed consent
* In good heath as determined by medical evaluation,
* Willing and able to comply with trial restrictions, procedures, and requirements
Exclusion Criteria:
* Known sensitivity to any components of the IMP
* History of relevant drug hypersensitivity
* Presents or has a history of clinically significant diseases
* History of difficulty swallowing tablets or capsules.
* Any physical examination findings or medical history that might place the participant at an unacceptable risk for participation in this trial.
Primary outcome measure(s)
Pharmacokinetics: Maximum Concentration (Cmax) — Day 1 to Day 18
Pharmacokinetics: Area Under the Concentration Curve (AUC) — Day 1 to Day 18
Pharmacokinetics: Trough Concentration (Ctrough) — Day 1 to Day 18
Pharmacokinetics: Half-life — Day 1 to Day 18
Pharmacokinetics: Time to Maximum Concentration (tmax) — Day 1 to Day 18
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.